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Abstract
Background: The treatment of bipolar disorder (BD) remains a challenge due to the complexity of the disease. Current
guidelines represent an effort to assist clinicians in routine practice but have several limitations, particularly concerning
long-term treatment. The ARIQUELI (efficacy and tolerability of the combination of lithium or aripiprazole in young
bipolar non or partial responders to quetiapine monotherapy) study aims to evaluate two different augmentation
strategies for quetiapine nonresponders or partial responders in acute and maintenance phases of BD treatment.
Methods/Design: The ARIQUELI study is a single-site, parallel-group, randomized, outcome assessor-blinded trial. BD I
patients according to the DSM-IV-TR, in depressive, manic/hypomanic or mixed episode, aged 18 to 40 years, are
eligible. After diagnostic assessments, patients initiated treatment in phase I with quetiapine. Nonresponders or partial
responders after 8 weeks are allocated into one of two groups, potentiated with either lithium (0.5 to 0.8 mEq/l) or
aripiprazole (10 or 15 mg). Patients will be followed up for 8 weeks in phase I (acute treatment), 6 months in phase II
(continuation treatment) and 12 months in phase III (maintenance treatment). Outcome assessors are blinded to the
treatment. The primary outcome is the evaluation of changes in mean scores on the CGI-BP-M between baseline and
the endpoint at the end of each study phase.
Discussion: The ARIQUELI study is currently in progress, with patients undergoing acute treatment (phase I),
potentiation (phase II) and maintenance (phase III). The study will be extended until January 2015. Trials comparing
lithium and aripiprazole with potentiate treatment in young BD I nonresponders to quetiapine in monotherapy can
provide relevant information on the safety of these drugs in clinical practice. Long-term treatment is an issue of great
importance and should be evaluated further through more in-depth studies given that BD is a chronic disease.
Trial registration: ClinicalTrials.gov identifier: NCT01710163
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Background
Bipolar disorder (BD) treatment is a focus of ongoing re-
search to further understanding of the clinical features
and possible pathophysiology of the disease. The multi-
variate factors associated with the etiology of BD,
coupled with the variability of clinical presentation,
hamper the determination of a specific treatment with
optimized outcomes (efficacy and tolerability). Difficul-
ties in BD treatment include delay in diagnosis, high
levels of comorbidity, frequent treatment nonadherence
and high risk of relapse/recurrence (particularly in the
presence of residual symptoms) [1].
Most currently available treatments focus on the acute
phase and use a reduction in symptoms ≥50% from
baseline as a measure of response. In fact, some re-
sponders to treatment continue to experience significant
subsyndromic symptoms. A small number of studies
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have reported remission rates, defined as ≥2 months
with no significant signs or symptoms of the disorder
[2]. Fewer studies, however, have reported remission
during the acute phase through to the maintenance
phase of treatment and its predictors [3], which are of
great clinical significance. Recent data show that BD
treatment under special conditions was associated with
full remission in only one-half of the patients and that
nearly one-half of the recovered patients relapsed at least
once during a 2-year follow up [4]. Maintenance treat-
ment is necessary in BD due to the high mortality, mor-
bidity risk and social and professional impairment
associated with poor outcomes [5].
As monotherapy, quetiapine has proven more effective
than lithium in the treatment of depression at doses ran-
ging from 150 to 600 mg [6,7], with no significant differ-
ence found between 300 and 600 mg doses [8]. The drug
has also shown similar efficacy in the treatment of mania
at doses of between 600 and 800 mg compared with lith-
ium after 4 weeks and with haloperidol after 84 days
[9-11], although response in mania was slower when
compared with haloperidol [11]. To date, quetiapine is
the only antipsychotic medication with evidence of effi-
cacy across all phases of bipolar disorder [7], and was re-
cently indicated as the first choice in monotherapy for
the treatment of bipolar depression [12,13].
On the other hand, lithium is the first-line choice for
the maintenance treatment of BD, particularly for classic
(euphoric) mania and bipolar depression, according to
many open controlled studies, with additional clinical ef-
fects such as antisuicidal properties, augmentation and
treatment of acute unipolar depression and recurrent de-
pression [14]. Some studies have shown lithium to be
more specific for manic and less effective for depressive
episodes [15] while an accumulating body of evidence
tends to support its specificity in psychiatric usage, par-
ticularly in patients with classic BD.
In Brazil, lithium is the first treatment choice in all BD
phases, representing a suitable and affordable treatment
option. However, treatment under the Brazilian Public
Health System (Sistema Único de Saúde) has financial lim-
itations, where atypical antipsychotics and some anticon-
vulsants are currently not made available for use in BD.
Few controlled studies on the most-used treatments for
the general population are therefore conducted compared
with trials involving the latter medications, which the
pharmaceutical industry has an interest in promoting [16].
Aripiprazole is an atypical antipsychotic with a single
mechanism of action that shows partial agonist activity
at dopamine D2 and D3 and serotonin 5-HT1A receptors,
as well as antagonist activity at serotonin 5-HT2A recep-
tors [17,18]. The drug is US Food and Drug Administra-
tion approved for the treatment of mania and
maintenance of BD 1, and has proven effective in several
trials for the adjunctive treatment of bipolar depression
and major depressive disorder [19-22].
Despite the drug’s proven efficacy in the treatment of
manic episodes [23], results of aripiprazole monotherapy
in bipolar depression have been poor, with benefits not
persisting beyond 8 weeks [24]. Some data, albeit not ro-
bust, suggest the drug’s efficacy as an adjunct for poten-
tializing treatment in bipolar I depression, although it is
unclear whether this response persists beyond the acute
phase [25].
Information in the general literature regarding aug-
mentation of treatments initially refractory in trials, as
well as on the combination of atypical antipsychotics in
acute and maintenance phases, remains scarce.
Methods/Design
The ARIQUELI project
The ARIQUELI (efficacy and tolerability of the combin-
ation of lithium or aripiprazole in young bipolar non or
partial responders to quetiapine monotherapy) study is a
randomized trial designed to assess the add-on therapies
of lithium or aripiprazole for augmentation of quetiapine
treatment.
Design of the ARIQUELI study
The two key elements of the ARIQUELI project were
based on the rationale described above. For the first
element, the disorder was considered as a whole; that is,
patients with different clinical presentations (such as de-
pression, mania or mixed episodes) shall receive the
same treatment. The treatment focus is relapse/recur-
rence prevention as opposed to treating a particular
phase. Patients are to undergo long-term follow-up
given that BD is a chronic and recurrent disorder. The
second key point is that comparing the augmentation
strategy using lithium versus aripiprazole should help
clarify the role of atypical antipsychotic drugs in the
treatment of BD.
This is a single-site, parallel-group, randomized, out-
come assessor-blinded trial. The study protocol was
reviewed and approved by the appropriate institutional
review board in accordance with the standards and
guidelines established in the current amendment of the
Declaration of Helsinki, and consistent with good clin-
ical practice and applicable regulatory requirements.
Written informed consent was obtained from all patients
prior to any study-related activities. Methodological de-
tails of all phases of the ARIQUELI study have been
presented in accordance with the Consolidated Standard
of Reporting Trials 2010 Statement [26].
The local institutional review board approved the
study (Hospital das Clinicas Ethical Committee,
CAPPESQ #26436). All subjects and/or family members
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provided written informed consent before entry into the
study.
Interventions
After diagnostic assessments, the patients initiate treat-
ment with quetiapine for 8 weeks as described above.
For acute treatment, patients shall receive a starting dos-
age of 100 mg on day 1, to be increased by 100 mg/day
to 300 mg on day 3. The 300 mg dose shall be subse-
quently adjusted until reaching the most effective dose
according to clinical criteria. The patient dose shall be
determined according to individual tolerability, and a
maximum dose of 800 mg will be allowed for this study.
Patients showing remission or >50% reduction in base-
line scores on the Hamilton Depression Scale and the
Young Mania Rating Scale shall proceed to the mainten-
ance phase for a further 18 months. Patients showing
score reductions <50% on the scales will be allocated to
one of the arms of the augmentation phase. Group I will
receive lithium at the standard dose: starting at 300 mg
daily, the weekly dose will be adjusted according to
blood serum level (between 0.5 and 0.8 mEq/l) according
to efficacy and tolerability. Group II will receive
aripiprazole: starting at 10 mg daily, the dose will be ad-
justed up to 15 mg daily according to efficacy and toler-
ability. The only concomitant medications permitted are
lorazepam at doses of 0.5 to 4 mg/day and biperiden at
2 to 8 mg/day.
Eligibility
Patients are recruited from within the Institute of Psych-
iatry, Clinicas Hospital of the University of Sao Paulo
School of Medicine. BD I patients according to DSM-IV-
TR [2], in depressive, manic/hypomanic or mixed episode,
aged 18 to 40 years, are eligible for the study. To be in-
cluded, patients must score at least 8 points on the
Hamilton Depression Scale or 10 points on the Young
Mania Rating Scale. Patients with comorbid conditions are
allowed to participate due to the real clinical study ap-
proach (‘more likely naturalistic study’). Patients in previ-
ous use of quetiapine and lithium or quetiapine and
aripiprazole combinations will not be included. Other ex-
clusion criteria include presenting with schizophrenia,
mental retardation (IQ <90) or unstable clinical conditions.
Eligible patients currently under pharmacological
treatments have to undergo a washout period according
to the medication in use: 1 week for antidepressants, an-
tipsychotics, lithium, valproate, carbamazepine and other
anticonvulsants; 2 weeks for irreversible MAOI; and
4 weeks for fluoxetine and clozapine.
Sample size and randomization
Sample size was calculated by comparing the mean differ-
ence in Clinical Global Impression for Bipolar Disorders
(CGI-BP-M) scores between baseline and endpoint for the
two groups. Comparison using Student's t test showed
that a sample of 50 patients (25 in each group) attains an
80% power (at 5% significance level) for detecting a differ-
ence of 0.8 standard deviations, considered a large effect
size [27]. Owing to the exploratory nature of this study
and the difficulties regarding compliance in long-term tri-
als, this was deemed an acceptable value [27].
The random allocation sequence was computer gener-
ated by a biostatistician. Patients were enrolled by clini-
cians who have their code revealed by the research
monitor when assigned to interventions. Blinding of out-
come assessors is ensured by keeping their evaluations
independent from those of the clinicians.
Study phases
Patients will be followed up for 8 weeks in phase I (acute
treatment), 8 weeks in phase II (potentiation treatment)
and shall continue in phase III (maintenance) until study
endpoint at 2 years. Scale raters will be blind to the
treatment. Only patients that respond will continue to
phase 3, with response determined according to the ini-
tial symptoms score in phase I. Patients in phase III
using quetiapine alone that present a new episode of any
polarity, as detected on two consecutive visits, will start
phase II (potentiation treatment). Patients that show no
response after phase II will be dropped from the study.
The definition of clinical course is defined as follows:
no response, reduction ≤25% in severity of symptoms;
partial response, improvement of 26 to 49% in symp-
toms; response, reduction ≥50% in severity of symptoms;
remission, minimal or no symptoms for at least 1 week,
Hamilton Depression Scale ≤7 and Young Mania Rating
Scale ≤9; sustained remission, ≥8 weeks of remission; re-
lapse/recurrence, return of the signs and symptoms for
the syndrome as per criteria; and worsening, return of
symptoms at subsyndromal level [28-30].
Primary outcomes
Primary outcome will consist of the evaluation of changes
in mean scores on the CGI-BP-M between baseline and
endpoint at the end of each phase of the study.
Secondary outcomes
Secondary outcome will include the proportion of pa-
tients that achieve remission and response to each treat-
ment at the end of each phase of the study, according to
improvement on the rating scales (Hamilton Depression
Scale; Montgomery–Åsberg Depression Rating Scale;
Young Mania Rating Scale) and in CGI-BP-M [31]. The
CGI-BP-M is a clinician rating scale modified for BD for
assessing treatment response and consists of three sub-
scales evaluating severity of mania, depression and glo-
bal disease symptoms.
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Other outcome parameters include safety and toler-
ability, quality of life and social adjustment, and cogni-
tive impairment. These parameters will be evaluated by
comparing the endpoint measures for each phase with
baseline values. Safety and tolerability were determined
according to the clinical evaluation of adverse effects
and score on the UKU side-effect rating scale [32]. The
UKU comprises a 48-item clinician rated scale evaluat-
ing side effects in psychic, neurologic, autonomic and
other domains. Quality of life and social adjustment
were measured with the WHOQoL-BREF [33] and the
Social Adjustment Scale [34]. These instruments were
previously translated and validated into Portuguese
[35,36]. The WHO-QOL-BREF is a 26-item self-report
scale comprising four domains: physical, psychological,
social, and environmental. The Social Adjustment Scale
is a 54-question self-report instrument that measures in-
strumental and expressive role performance over the
previous 2 weeks. Cognitive impairment was measured
neuropsychological tests (Wisconsin Card Sorting Test,
Stroop Color Word Test [37], Wechsler Abbreviated
Scale of Intelligence [38], Trail Making Test [37] and
others), for which versions are available in Portuguese.
All investigators received appropriate training, and inter-
rater reliability is periodically assessed.
Planned analyses
The primary analysis will entail evaluation of mean scores
on the CGI-BP-M between baseline and endpoint in both
groups. In addition, differences shall be evaluated by com-
paring the two treatment groups according to the total
number of patients in full remission at the study endpoint
and the reason for and timing of drop out. Continuous
data will be represented as mean and standard deviation
whereas categorical variables will be described by a table
of frequencies. The results of all statistical comparisons of
the treatment groups will be expressed as two-sided
P values rounded to three decimal places. The criterion for
statistical significance in all comparisons will be P ≤0.05.
Continuous variables will be compared using repeated-
measures of analysis of variance, with the treatment
group and study phase as factors. Rates of response, re-
mission and dropouts will be compared between the two
groups using Pearson's chi-square test for categorical
data. Dichotomous measures will also be compared
using odds ratios and 95% confidence limits.
The correlation of clinical issues, quality of life, social
adjustment and cognitive impairment will be evaluated
by Pearson's correlation.
Discussion
Trials comparing specific treatment efficacy in BD (head
to head) can show relevant information in clinical
practice.
Typical limitations in clinical trials include: specific
clinical forms of BD (mania/mixed or depression) for
each treatment tested; scant information available on
how treatment in the acute phase should progress to
maintenance or which factors in acute treatment predict
recurrence during maintenance treatment; and hetero-
geneity of patients, considering the course of illness
(chronic versus nonchronic) in clinical trials can mask
important treatment implications for specific popula-
tions (younger versus older, for example).
Owing to the substantial increase in treatment options,
specific guidelines and algorithms are used in an effort
to enhance the cost-effectiveness of care by minimizing
the number of treatment options employed [28]. Despite
limitations inherent to the use of these algorithms, they
represent the available data concerning the levels of evi-
dence for each treatment option.
Further evidence-based knowledge concerning aug-
mentation strategies and maintenance therapy using
combination treatments is needed in clinical practice.
Current trial status
The ARIQUELI study is currently in progress, with pa-
tients in phases I, II and III, and is to be extended for a
further 2 years.
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